Arterial Thromboembolism
0
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
BayerLEVERKUSEN, Germany
1 programLong-term Active Surveillance Study for Oral Contraceptives (LASS)N/A1 trial
Active Trials
LeMaitre VascularAustralia - Docklands
1 programTufTex Single Lumen Embolectomy CatheterN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Imperative CareProdigy Thrombectomy System
LeMaitre VascularTufTex Single Lumen Embolectomy Catheter
BayerLong-term Active Surveillance Study for Oral Contraceptives (LASS)
Clinical Trials (3)
Total enrollment: 59,165 patients across 3 trials
Aspiration Thrombectomy Using the Symphony or Prodigy System
Start: Feb 2026Est. completion: Sep 2030750 patients
N/ARecruiting
A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter
Start: Jan 2022Est. completion: Jun 2027112 patients
N/ARecruiting
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
Start: Feb 2001Est. completion: Dec 201158,303 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 59,165 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.